Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardant Health, Inc. (Nasdaq: GH), a precision oncology company based in Palo Alto, California. Through these filings, investors and analysts can review the company’s official disclosures about its capital structure, governance, and key events related to its blood and tissue tests, real-world data activities, and AI analytics in cancer care.
Guardant Health’s common stock is registered on The Nasdaq Global Select Market under the symbol GH, as noted in its Form 8-K filings. The company files current reports on Form 8-K to describe material events, such as public offerings of common stock, private offerings of convertible senior notes, results of stockholder meetings, financial results announcements, and board appointments. These documents outline details like underwriting agreements, convertible note terms, and voting outcomes at annual meetings.
In addition to Form 8-K reports, Guardant Health files annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain more extensive information about its business, risk factors, and financial statements. Proxy statements on Schedule 14A provide further detail on governance matters and executive compensation. Together, these filings offer a regulatory record of how the company finances its operations, manages its corporate governance, and communicates significant developments to the market.
On Stock Titan, Guardant Health’s SEC filings are updated as they are made available through the EDGAR system. AI-powered tools can help summarize long documents, highlight key terms in offerings and note indentures, and make it easier to locate information on topics such as capital raises, voting results, and reporting obligations. This page is intended as a convenient starting point for reviewing Guardant Health’s regulatory disclosures in one place.
Guardant Health (GH) director Steve Krognes reported a Form 4 for an RSU conversion on 10/31/2025. A restricted stock unit vested and settled into 154 shares of common stock at a stated price of $0 (transaction code M). Following the transaction, he directly beneficially owned 18,436 shares of common stock and held 1,235 RSUs as derivative securities.
The RSU grant was made on August 9, 2022, with 25% vesting on June 30, 2023, and the remaining 75% vesting in substantially equal monthly installments over the next three years. The filing was made by one reporting person in his capacity as a Director.
Guardant Health (GH) filed its Q3 2025 10-Q, reporting higher revenue and a narrower loss. Revenue rose to $265,196,000 from $191,476,000 a year ago, while net loss improved to $92,725,000 from $107,754,000. Loss per share was $0.74 versus $0.88.
Growth was broad-based: Oncology revenue was $184,402,000, Biopharma and data $54,731,000, Screening $24,112,000, and Licensing and other $1,951,000. For the nine months, revenue totaled $700,755,000, with a net loss of $287,783,000.
Cash and cash equivalents were $580,013,000, with restricted cash of $109,502,000; total assets were $1,276,786,000. Operating cash outflow for the nine months was $158,387,000. The company exchanged $659,300,000 of 2027 notes for $600,000,000 of 1.25% notes due 2031, recording a $13,672,000 gain and leaving $490,700,000 of 2027 notes outstanding. Treasury stock repurchases were $45,010,000 for 976,351 shares. As of October 24, 2025, 126,041,089 common shares were outstanding.
Guardant Health, Inc. furnished an update on its latest results by submitting a Form 8-K. On October 29, 2025, the company issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025, and attached the full text of that release as Exhibit 99.1. The disclosure clarifies that this information, including the exhibit, is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.
Guardant Health (GH) reported an insider equity change. Director Roberto A. Mignone had 3,167 shares of Common Stock acquired on 10/21/2025 via a code M transaction, reflecting the conversion of restricted stock units at a price of $0.
Following the transaction, the filing lists 3,167 Common Stock shares beneficially owned in direct form. The derivative table shows 9,504 Restricted Stock Units beneficially owned after the event. The RSU grant from November 8, 2024 vests over four years: 25% on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) director Manuel Hidalgo Medina reported the vesting and settlement of restricted stock units into 232 shares of Common Stock on 10/17/2025 (transaction code M) at $0 per share.
Following the transaction, he directly owned 1,315 shares of Common Stock and held 7,657 RSUs outstanding. The RSU grant dated July 17, 2024 vests over four years: 25% vested on the one-year anniversary of July 17, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) reported an insider transaction on a Form 4. A company director sold 116 shares of common stock at $66.95 on 10/17/2025. Following the sale, the reporting person directly holds 7,725 shares.
Guardant Health (GH) filed a Form 4 disclosing an insider sale. Director Myrtle S. Potter sold 26 shares of common stock on 10/17/2025 at $66.95 per share. After this transaction, she directly beneficially owns 18,324 shares. The filing lists the ownership form as direct and does not report any derivative security activity.
Guardant Health (GH)October 15, 2025, 69 shares of Common Stock were acquired at $0 upon the vesting and settlement of Restricted Stock Units (RSUs) (transaction code M). Following this, the director directly owned 18,350 shares.
The RSU award vested 25% on October 15, 2022, with the remaining 75% vesting in substantially equal monthly installments over the next three years.
Guardant Health (GH) director reports Form 4 activity. On 10/15/2025, 250 shares of common stock were acquired at $0 following the settlement of restricted stock units (transaction code M). After this transaction, the reporting person directly owns 7,841 shares.
The related derivative line shows 250 restricted stock units converted into 250 shares at $0 on 10/15/2025, leaving 4,248 derivative securities (restricted stock units) directly beneficially owned after the event.
The award referenced in the footnotes was granted on March 6, 2023 and vests over four years: 25% vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the following three years.
Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported multiple equity transactions dated 10/01/2025. He had 13,550 restricted stock units vest or be credited (1,928; 1,668; 9,954) and a separate purchase of 5,740 shares at $62.65. The company retained 5,740 shares to satisfy the tax withholding related to one vesting installment; the filer notes the retained amount did not exceed the tax liability. Following the reported transactions, Freeman beneficially owned 63,179 shares (direct ownership). The Form 4 was signed by an attorney-in-fact on behalf of Mr. Freeman on 10/02/2025.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
